Risk of secondary T-cell malignancy after CAR T-cell therapy
Drug and Therapeutics Bulletin · 2025
DOI: 10.1136/dtb.2025.000023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, 2025. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Second Primary, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Overview of: European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024 [Accessed 22 May 2025].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2025). Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2025.000023
Vancouver
Risk of secondary T-cell malignancy after CAR T-cell therapy. Drug and Therapeutics Bulletin. 2025. doi:10.1136/dtb.2025.000023
BibTeX
@article{euvimed2025,
title = {Risk of secondary T-cell malignancy after CAR T-cell therapy},
journal = {Drug and Therapeutics Bulletin},
year = {2025},
doi = {10.1136/dtb.2025.000023}
}
EUVIMED